Approval for Hexvix obtained in Italy
Oslo, Norway, June 19th, 2007 - Photocure ASA (OSE:PHO) today announces that Hexvix has received marketing approval and price approval in Italy. This final approval triggers a milestone payment of 0.5 million from GE Healthcare who holds exclusive global rights outside of the Nordic region to market and distribute Photocure's product Hexvix.
Hexvix is being introduced in Europe and price/reimbursement is approved in other key countries as Spain and France.
President and CEO of Photocure, Kjetil Hestdal comments: "Obtaining this approval in Italy means that the entire European market is open for marketing and sales of Hexvix."
For further information, contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
Office: +47 22 06 22 10
CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
Office: +47 22 06 22 10
www.photocure.com
Photocure is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the treatment and diagnosis of different types of cancer. The products are based on proprietary photodynamic technologies, targeting specific dermatology and oncology markets.
Photocure has currently two pharmaceutical products on the market: Metvix®, for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix®, for the diagnosis of bladder cancer. In addition, the company has developed a proprietary light source, the Aktilite® lamp, which is used in combination with the Metvix cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products and technologies.